Enhanced cytotoxicity in triple-negative and estrogen receptor‑positive breast adenocarcinoma cells due to inhibition of the transient receptor potential melastatin-2 channel

Koh,David  W.; Powell,Daniel   P.; Blake,Steven  D.; Hoffman,Joy  L.; Hopkins,Mandi  M.; Feng,Xiaoxing

doi:10.3892/or.2015.4131

Enhanced cytotoxicity in triple-negative and estrogen receptor‑positive breast adenocarcinoma cells due to inhibition of the transient receptor potential melastatin-2 channel

Authors:
- David W. Koh
- Daniel P. Powell
- Steven D. Blake
- Joy L. Hoffman
- Mandi M. Hopkins
- Xiaoxing Feng
View Affiliations

Affiliations: Department of Pharmaceutical and Biomedical Sciences, Ohio Northern University, Ada, OH 45810, USA, Department of Pharmaceutical Sciences, Washington State University, Pullman, WA 99164, USA
Published online on: July 14, 2015 https://doi.org/10.3892/or.2015.4131
Pages: 1589-1598

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

We previously demonstrated a unique protective role for the transient receptor potential, melastatin-2 (TRPM2) cation channel in breast cancer cells. In the present study, we investigated the chemotherapeutic effects elicited by inhibiting this protective role in metastatic breast adenocarcinoma cells. TRPM2 inhibition led to dose-dependent increases in MDA-MB-231 breast adenocarcinoma cell death after treatment with doxorubicin or the DNA-methylating agent, N-methyl-N'-nitro-N-nitrosoguanidine. Similar results were observed after RNAi silencing of TRPM2 in these cells after doxorubicin treatment. However, TRPM2 RNAi silencing also led to increased MCF-7 breast adenocarcinoma cell death after tamoxifen treatment, yet not in non-cancerous human mammary epithelial cells. These results thus revealed that TRPM2 inhibition selectively increased cytotoxicity in a triple-negative and an estrogen receptor-positive breast cancer cell line, with minimal deleterious effects in non-cancerous breast cells. Analysis of DNA damage revealed enhanced DNA damage levels in MCF-7 cells treated with doxorubicin due to TRPM2 inhibition. Analysis of cell death demonstrated that inhibition of apoptosis, caspase-independent cell death or autophagy failed to significantly reduce cell death induced by TRPM2 inhibition and chemotherapy. These results indicate that TRPM2 inhibition activates alternative pathways of cell death in breast cancer cells. Taken together, our results provide significant evidence that TRPM2 inhibition is a potential strategy to induce triple-negative and estrogen receptor-positive breast adenocarcinoma cell death via alternative cell death pathways. This is expected to provide a basis for inhibiting TRPM2 for the improved treatment of breast cancer, which potentially includes treating breast tumors that are resistant to chemotherapy due to their evasion of apoptosis.

View Figures

View References

1	Batist G, Harris L, Azarnia N, Lee LW and Daza-Ramirez P: Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: Results of a retrospective analysis. Anticancer Drugs. 17:587–595. 2006. View Article : Google Scholar : PubMed/NCBI
2	Harris LN, Broadwater G, Lin NU, Miron A, Schnitt SJ, Cowan D, Lara J, Bleiweiss I, Berry D, Ellis M, et al: Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: Results from CALGB 9342. Breast Cancer Res. 8:R662006. View Article : Google Scholar : PubMed/NCBI
3	Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL and Liu ET: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA. 100:10393–10398. 2003. View Article : Google Scholar : PubMed/NCBI
4	André F and Zielinski CC: Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann Oncol. 23(Suppl 6): vi46–vi51. 2012. View Article : Google Scholar : PubMed/NCBI
5	Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 365:1687–1717. 2005. View Article : Google Scholar : PubMed/NCBI
6	Fisher B, Anderson S, Tan-Chiu E, Wolmark N, Wickerham DL, Fisher ER, Dimitrov NV, Atkins JN, Abramson N, Merajver S, et al: Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol. 19:931–942. 2001.PubMed/NCBI
7	Dunnwald LK, Rossing MA and Li CI: Hormone receptor status, tumor characteristics, and prognosis: A prospective cohort of breast cancer patients. Breast Cancer Res. 9:R62007. View Article : Google Scholar : PubMed/NCBI
8	Lumachi F, Brunello A, Maruzzo M, Basso U and Basso SM: Treatment of estrogen receptor-positive breast cancer. Curr Med Chem. 20:596–604. 2013. View Article : Google Scholar : PubMed/NCBI
9	Parise CA and Caggiano V: Breast cancer survival defined by the ER/PR/HER2 subtypes and a surrogate classification according to tumor grade and immunohistochemical biomarkers. J Cancer Epidemiol. 2014:4692512014. View Article : Google Scholar : PubMed/NCBI
10	Cory S and Adams JM: The Bcl2 family: Regulators of the cellular life-or-death switch. Nat Rev Cancer. 2:647–656. 2002. View Article : Google Scholar : PubMed/NCBI
11	Aird KM, Ghanayem RB, Peplinski S, Lyerly HK and Devi GR: X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor. Mol Cancer Ther. 9:1432–1442. 2010. View Article : Google Scholar : PubMed/NCBI
12	Wang MY, Chen PS, Prakash E, Hsu HC, Huang HY, Lin MT, Chang KJ and Kuo ML: Connective tissue growth factor confers drug resistance in breast cancer through concomitant up-regulation of Bcl-xL and cIAP1. Cancer Res. 69:3482–3491. 2009. View Article : Google Scholar : PubMed/NCBI
13	Nadler MJ, Hermosura MC, Inabe K, Perraud AL, Zhu Q, Stokes AJ, Kurosaki T, Kinet JP, Penner R, Scharenberg AM, et al: LTRPC7 is a Mg·ATP-regulated divalent cation channel required for cell viability. Nature. 411:590–595. 2001. View Article : Google Scholar : PubMed/NCBI
14	Perraud AL, Fleig A, Dunn CA, Bagley LA, Launay P, Schmitz C, Stokes AJ, Zhu Q, Bessman MJ, Penner R, et al: ADP-ribose gating of the calcium-permeable LTRPC2 channel revealed by Nudix motif homology. Nature. 411:595–599. 2001. View Article : Google Scholar : PubMed/NCBI
15	Blenn C, Wyrsch P, Bader J, Bollhalder M and Althaus FR: Poly(ADP-ribose)glycohydrolase is an upstream regulator of Ca²⁺ fluxes in oxidative cell death. Cell Mol Life Sci. 68:1455–1466. 2011. View Article : Google Scholar :
16	Sun L, Yau HY, Wong WY, Li RA, Huang Y and Yao X: Role of TRPM2 in H₂O₂-induced cell apoptosis in endothelial cells. PLoS One. 7:e431862012. View Article : Google Scholar
17	Zhang W, Chu X, Tong Q, Cheung JY, Conrad K, Masker K and Miller BA: A novel TRPM2 isoform inhibits calcium influx and susceptibility to cell death. J Biol Chem. 278:16222–16229. 2003. View Article : Google Scholar : PubMed/NCBI
18	Lange I, Yamamoto S, Partida-Sanchez S, Mori Y, Fleig A and Penner R: TRPM2 functions as a lysosomal Ca²⁺-release channel in beta cells. Sci Signal. 2:ra232009. View Article : Google Scholar
19	Zhang W, Hirschler-Laszkiewicz I, Tong Q, Conrad K, Sun SC, Penn L, Barber DL, Stahl R, Carey DJ, Cheung JY, et al: TRPM2 is an ion channel that modulates hematopoietic cell death through activation of caspases and PARP cleavage. Am J Physiol Cell Physiol. 290:C1146–C1159. 2006. View Article : Google Scholar
20	Orfanelli U, Wenke AK, Doglioni C, Russo V, Bosserhoff AK and Lavorgna G: Identification of novel sense and antisense transcription at the TRPM2 locus in cancer. Cell Res. 18:1128–1140. 2008. View Article : Google Scholar : PubMed/NCBI
21	Chen SJ, Hoffman NE, Shanmughapriya S, Bao L, Keefer K, Conrad K, Merali S, Takahashi Y, Abraham T, Hirschler-Laszkiewicz I, et al: A splice variant of the human ion channel TRPM2 modulates neuroblastoma tumor growth through hypoxia-inducible factor (HIF)-1/2α. J Biol Chem. 289:36284–36302. 2014. View Article : Google Scholar : PubMed/NCBI
22	Zeng X, Sikka SC, Huang L, Sun C, Xu C, Jia D, Abdel-Mageed AB, Pottle JE, Taylor JT and Li M: Novel role for the transient receptor potential channel TRPM2 in prostate cancer cell proliferation. Prostate Cancer Prostatic Dis. 13:195–201. 2010. View Article : Google Scholar :
23	Hopkins MM, Feng X, Liu M, Parker LP and Koh DW: Inhibition of the transient receptor potential melastatin-2 channel causes increased DNA damage and decreased proliferation in breast adenocarcinoma cells. Int J Oncol. 46:2267–2276. 2015.PubMed/NCBI
24	Hiroi T, Wajima T, Negoro T, Ishii M, Nakano Y, Kiuchi Y, Mori Y and Shimizu S: Neutrophil TRPM2 channels are implicated in the exacerbation of myocardial ischaemia/reperfusion injury. Cardiovasc Res. 97:271–281. 2013. View Article : Google Scholar
25	Liu T, Biddle D, Hanks AN, Brouha B, Yan H, Lee RM, Leachman SA and Grossman D: Activation of dual apoptotic pathways in human melanocytes and protection by survivin. J Invest Dermatol. 126:2247–2256. 2006. View Article : Google Scholar : PubMed/NCBI
26	Blenn C, Althaus FR and Malanga M: Poly(ADP-ribose) glycohydrolase silencing protects against H₂O₂-induced cell death. Biochem J. 396:419–429. 2006. View Article : Google Scholar : PubMed/NCBI
27	Zhou Y, Feng X and Koh DW: Enhanced DNA accessibility and increased DNA damage induced by the absence of poly(ADP-ribose) hydrolysis. Biochemistry. 49:7360–7366. 2010. View Article : Google Scholar : PubMed/NCBI
28	Hartmann A, Agurell E, Beevers C, Brendler-Schwaab S, Burlinson B, Clay P, Collins A, Smith A, Speit G, Thybaud V, et al 4th International Comet Assay Workshop: Recommendations for conducting the in vivo alkaline Comet assay. 4th International Comet Assay Workshop. Mutagenesis. 18:45–51. 2003. View Article : Google Scholar
29	Olive PL, Banáth JP, Durand RE and Banath JP: Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the 'comet' assay. Radiat Res. 122:86–94. 1990. View Article : Google Scholar : PubMed/NCBI
30	Pinsky SD, Tew KD, Smulson ME and Woolley PV III: Modification of L1210 cell nuclear proteins by 1-methyl-1-nitro-sourea and 1-methyl-3-nitro-1-nitrosoguanidine. Cancer Res. 39:923–928. 1979.PubMed/NCBI
31	Kraft R, Grimm C, Frenzel H and Harteneck C: Inhibition of TRPM2 cation channels by N-(p-amylcinnamoyl)anthranilic acid. Br J Pharmacol. 148:264–273. 2006. View Article : Google Scholar : PubMed/NCBI
32	Konrad RJ, Jolly YC, Major C and Wolf BA: Inhibition of phospholipase A₂ and insulin secretion in pancreatic islets. Biochim Biophys Acta. 1135:215–220. 1992. View Article : Google Scholar : PubMed/NCBI
33	Rosenthal MD, Lattanzio KS and Franson RC: The effects of the phospholipase A₂ inhibitors aristolochic acid and PGBx on A23187-stimulated mobilization of arachidonate in human neutrophils are overcome by diacylglycerol or phorbol ester. Biochim Biophys Acta. 1126:319–326. 1992. View Article : Google Scholar : PubMed/NCBI
34	Togashi K, Inada H and Tominaga M: Inhibition of the transient receptor potential cation channel TRPM2 by 2-aminoethoxy-diphenyl borate (2-APB). Br J Pharmacol. 153:1324–1330. 2008. View Article : Google Scholar : PubMed/NCBI
35	Singh NP, McCoy MT, Tice RR and Schneider EL: A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res. 175:184–191. 1988. View Article : Google Scholar : PubMed/NCBI
36	Caserta TM, Smith AN, Gultice AD, Reedy MA and Brown TL: Q-VD-Oph, a broad spectrum caspase inhibitor with potent antiapoptotic properties. Apoptosis. 8:345–352. 2003. View Article : Google Scholar : PubMed/NCBI
37	Seglen PO and Gordon PB: 3-Methyladenine: Specific inhibitor of autophagic/lysosomal protein degradation in isolated rat hepatocytes. Proc Natl Acad Sci USA. 79:1889–1892. 1982. View Article : Google Scholar : PubMed/NCBI
38	Yu SW, Wang H, Poitras MF, Coombs C, Bowers WJ, Federoff HJ, Poirier GG, Dawson TM and Dawson VL: Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science. 297:259–263. 2002. View Article : Google Scholar : PubMed/NCBI
39	Dantzer F, de La Rubia G, Ménissier-De Murcia J, Hostomsky Z, de Murcia G and Schreiber V: Base excision repair is impaired in mammalian cells lacking poly(ADP-ribose) polymerase-1. Biochemistry. 39:7559–7569. 2000. View Article : Google Scholar : PubMed/NCBI
40	Trucco C, Oliver FJ, de Murcia G and Ménissier-de Murcia J: DNA repair defect in poly(ADP-ribose) polymerase-deficient cell lines. Nucleic Acids Res. 26:2644–2649. 1998. View Article : Google Scholar : PubMed/NCBI
41	Zhou Y, Feng X and Koh DW: Activation of cell death mediated by apoptosis-inducing factor due to the absence of poly(ADP-ribose) glycohydrolase. Biochemistry. 50:2850–2859. 2011. View Article : Google Scholar : PubMed/NCBI
42	Andrabi SA, Kim NS, Yu SW, Wang H, Koh DW, Sasaki M, Klauss JA, Otsuka T, Zhang Z, Koehler RC, et al: Poly(ADP-ribose) (PAR) polymer is a death signal. Proc Natl Acad Sci USA. 103:18308–18313. 2006. View Article : Google Scholar : PubMed/NCBI
43	Buelow B, Song Y and Scharenberg AM: The Poly(ADP-ribose) polymerase PARP-1 is required for oxidative stress-induced TRPM2 activation in lymphocytes. J Biol Chem. 283:24571–24583. 2008. View Article : Google Scholar : PubMed/NCBI
44	Miller BA, Hoffman NE, Merali S, Zhang XQ, Wang J, Rajan S, Shanmughapriya S, Gao E, Barrero CA, Mallilankaraman K, et al: TRPM2 channels protect against cardiac ischemia-reperfusion injury: Role of mitochondria. J Biol Chem. 289:7615–7629. 2014. View Article : Google Scholar : PubMed/NCBI